FBLG FIBROBIOLOGICS INC.

FibroBiologics to Present at the 2025 ThinkEquity Conference

FibroBiologics to Present at the 2025 ThinkEquity Conference

HOUSTON, Oct. 14, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Founder and Chief Executive Officer, Pete O’Heeron, will present at the 2025 ThinkEquity Conference taking place October 30 at the Mandarin Oriental in New York City.

FibroBiologics will deliver a company presentation at 4:30 p.m. ET on October 30 and will be available for one-on-one investor meetings throughout the event.

For more information, please visit FibroBiologics'  or email FibroBiologics at: .

About FibroBiologics

Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 270+ US and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy and tissue regeneration. For more information, visit .

General Inquiries:

Investor Relations:

Nic Johnson

Russo Partners

(212) 845-4242

Media Contact:

Liz Phillips

Russo Partners

(347) 956-7697



EN
14/10/2025

Underlying

FBLGFIBROBIOLOGICS INC.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on FIBROBIOLOGICS INC.

 PRESS RELEASE
Free
FBLG FIBROBIOLOGICS ...

FibroBiologics Reports Third Quarter 2025 Financial Results and Provid...

FibroBiologics Reports Third Quarter 2025 Financial Results and Provides Corporate Update Advancing preparations to begin manufacturing of fibroblast-based spheroids product candidate, CYWC628, for the Phase 1/2 clinical trial evaluating CYWC628 in diabetic foot ulcers (DFU) patients  Preparing to submit Investigational New Drug applications for the treatment of psoriasis with CYPS317 and the treatment of multiple sclerosis with CYMS101 HOUSTON, Oct. 31, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ pat...

October 31, 2025 1 EN
 PRESS RELEASE
Free
FBLG FIBROBIOLOGICS ...

FibroBiologics to Present at Bio-Europe 2025

FibroBiologics to Present at Bio-Europe 2025 HOUSTON, Oct. 24, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Founder and Chief Executive Officer, Pete O’Heeron, will present at the Bio-Europe 2025 conference taking place November 3-5, 2025, at the Vienna Congress and Convention Center in Vienna, Austria. FibroBiologics ...

October 24, 2025 1 EN
 PRESS RELEASE
Free
FBLG FIBROBIOLOGICS ...

FibroBiologics to Present at the 2025 ThinkEquity Conference

FibroBiologics to Present at the 2025 ThinkEquity Conference HOUSTON, Oct. 14, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Founder and Chief Executive Officer, Pete O’Heeron, will present at the 2025 ThinkEquity Conference taking place October 30 at the Mandarin Oriental in New York City. FibroBiologics will deliver a...

October 14, 2025 1 EN
 PRESS RELEASE
Free
FBLG FIBROBIOLOGICS ...

FibroBiologics to Present at 2025 Cell & Gene Meeting on the Mesa

FibroBiologics to Present at 2025 Cell & Gene Meeting on the Mesa HOUSTON, Sept. 23, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Chief Scientific Officer, Hamid Khoja, Ph.D., will present at the 2025 Cell & Gene Meeting on the Mesa Conference taking place October 6-8 in Phoenix, Arizona. “The Cell & Gene Meeting on th...

September 23, 2025 1 EN
 PRESS RELEASE
Free
FBLG FIBROBIOLOGICS ...

FibroBiologics Leadership Authors Opinion Editorial Highlighting Fibro...

FibroBiologics Leadership Authors Opinion Editorial Highlighting Fibroblast Cells' Therapeutic Advantages Over Traditional Stem Cell Therapies HOUSTON, Sept. 12, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced the publication of an opinion editorial authored by company leadership that presents the scientific case for fibroblast...

September 12, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch